BioSpace News Archive

Sigilon Therapeutics today announced the formation of a scientific advisory board.

MEBIAS Discovery, an emerging leader in the field of biased agonism G-Protein Coupled Receptor (GPCR) drug discovery, presented preclinical data on two novel drug candidates at the Academic Drug Discovery Consortium on October 12, 2017.

Ipsen and its partner Exelixis today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS)

Agile Therapeutics today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla.

Aimmune Therapeutics, Inc., today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to study AR101 treatment with adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical trial.

Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.

Rebiotix today announced new clinical findings from the RBX2660 Phase 2 program that are being presented in three poster presentations at the World Congress of Gastroenterology at ACG2017 in Orlando, Fl.

AAVP Biosystems, a development stage gene therapy company focused on the pursuit of new targeted therapeutics for cancer indications, is pleased to announce the formation of its Medical Advisory Board.

Takeda today announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), particularly in biologic-naïve patients for whom other therapies have not worked well enough.

Medizone Internationalor Medizone, manufacturer of the AsepticSure Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure System